Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
about
Multidisciplinary meeting on male breast cancer: summary and research recommendationsProgress in adjuvant chemotherapy for breast cancer: an overviewAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineAdjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patientsDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Postoperative delirium in a substudy of cardiothoracic surgical patients in the BAG-RECALL clinical trial.Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk predictionComparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Treatment options for patients with triple-negative breast cancerBenefit risk assessment and update on the use of docetaxel in the management of breast cancer.Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial.Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsComparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancerTriple-negative and basal-like breast cancer: implications for oncologists.Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialA multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 studyExtended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialPrognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational studyEvidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewWhy values elicitation techniques enable people to make informed decisions about cancer trial participation.ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumoursThe Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer.A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialDo anthracyclines still have a role in adjuvant chemotherapy of breast cancer?Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.Optimal adjuvant chemotherapy in breast cancer: selection of agents.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Dermatological adverse events with taxane chemotherapy.TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.
P2860
Q24631800-060C9F4D-A96C-4BC2-A013-355B00CA2372Q26798078-3D5175F0-3B75-4C80-A822-43EA40038DCEQ26853619-88B0190B-10D0-4DF4-8EF9-8418B82629E6Q28477739-F720F1E1-F8E0-46A8-84C8-6C271B744370Q28728830-329C0C97-8447-43CD-831A-5CE7B30B8C84Q30318240-34CB5AC2-E9A3-4AB5-B79A-D473673CC815Q33577664-3E8080FB-2F35-4BF8-8F56-AD8E0D3A1C81Q33847811-996C6F26-C17C-4A3E-AD2C-0D9C359B7B37Q34199348-452F014B-2947-48F4-8744-A8EB769D402EQ34331406-0F03A68B-E416-4C1F-879E-5C6D901D520AQ34379034-C32D8C7B-A4CA-4C4B-98BD-9C69B595A9F1Q35041318-BDCCE16C-D00B-4139-9786-18F7D19BDE9CQ35059932-F765F9D7-1E33-47E2-8B5F-49E19D8FB05EQ35100315-BC239816-EF47-401C-8435-EAD0B2E3EA1FQ35142230-058587E8-8617-4066-A681-6F5876121B81Q35145642-F66FD468-66F0-41DF-971A-1BD1492B827CQ35145663-45F824C1-7047-4BB9-A151-1CEDD1AE7D87Q35345516-12FD8667-8065-4AFF-B7BC-368D50B2B6C9Q35889568-2AFFE1BD-F581-4F44-A52B-309CC91392BAQ35994850-E2EF8685-CACF-4069-AF1F-85429EC76670Q36102798-D8AC5B73-C20D-47BB-BB2C-54628250F671Q36245341-6936BF8A-E904-4B2F-B40D-C324FEEC7827Q36432567-35FADFF4-D1CD-44D1-8118-EECF3C5FFCBAQ36671882-A17EAF36-71D0-44A5-AB4A-5A90DDCB534AQ37263598-7C380946-42B2-4FDD-87B9-6108ECECC538Q37298361-7D86179B-AEEC-4559-98F2-F49ECD2B1A98Q37309845-69CC52F4-2A19-4385-B283-B7FABAB7F048Q37325532-D357A4BF-2560-4528-98B8-AC17793BAA92Q37452750-B801D45C-3D17-4718-99FC-109E4F550E07Q37552663-63C53455-AC1A-45AA-99BE-31D3A2793A7EQ37580175-2B0B9C79-D9D9-43A0-90CB-03C9DF70A6D8Q37822734-7E62406D-A94D-4D3B-938E-D5E8384C7581Q37903140-C076312E-4AAB-46CC-88D3-7158990E5951Q38017967-51AC72F6-B516-4860-B303-396EC0FDBC1DQ38235713-D4A76162-704F-4B4B-A104-AC8CBDA9AF12Q38454847-DA756BFF-27A2-454F-A46E-B95111CC06ECQ38682028-EC4308D9-00B2-40ED-B171-C6303323F364Q38934447-8829BB3F-5CC4-49DC-84E6-6A78C8C5EADAQ39719978-C7716698-E3B6-4E5B-85A0-EA7FF1B33352Q40137270-484A6548-456C-4944-9FB8-1D013599D624
P2860
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en-gb
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@nl
type
label
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en-gb
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@nl
prefLabel
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en-gb
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@nl
P2093
P2860
P50
P1433
P1476
Sequential docetaxel as adjuva ...... , randomised controlled trial.
@en
P2093
Chris Twelves
Christopher Poole
Clare Peckitt
David Bloomfield
David Cameron
John M S Bartlett
John Yarnold
Judith M Bliss
Lindsay Johnson
P2860
P304
P356
10.1016/S0140-6736(09)60740-6
P407
P577
2009-05-01T00:00:00Z